SuperworthTELA Bio price to book ratio TELA
Market value divided by the book value of the company's net assets, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 7.2×
- May 2026
- 7-year median
- 6.3×
- 7-year range
- 1.3× to 86.9×
- Peer median
- 2.6×
TELA Bio's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in May 2026, at 7.2×.
On the days it had one over the last 7 years, its median was 6.3×, from 1.3× in Apr 2025 to 86.9× in Jun 2023.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.2× | 4.0× | 29.5× |
| 2025 | 29.5× | 1.3× | 30.3× |
| 2024 | 26.5× | 4.3× | 26.8× |
| 2023 | 5.3× | 2.8× | 86.9× |
| 2022 | 9.5× | 6.0× | 12.6× |
| 2021 | 6.7× | 3.7× | 6.8× |
| 2020 | 3.9× | 2.9× | 10.6× |
Against its peers
Companies in Medical - Instruments & Supplies nearest TELA Bio's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| TELATELA Bio | n/m |
| NEPHNephros | 3.2× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| UTMDUtah Medical Products | 1.9× |
| INFUInfuSystem | 4.7× |
| EMBCEmbecta | n/m |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on TELA Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.